PROFESSIONAL EDITION

The largest community of pharma leaders

Dendreon Pharmaceuticals Appoints Sherry Saurini as Vice President of Quality

SEAL BEACH, Calif.–()–Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, is pleased to announce the appointment of Sherry Saurini as Vice President of Quality, effective August 23, 2021. Saurini will focus on leading and managing the strategic and operational performance of the quality organization to support Dendreon’s product portfolio and contract manufacturing services division partner programs.

“After launching our contract manufacturing services division earlier this year, we sought to enhance our industry-leading quality standards for both our core business and partner programs.” said Jason O’Neill, CEO of Dendreon Pharmaceuticals. “Sherry’s addition to our team solidifies our commitment to delivering the highest quality cell therapy products at commercial scale to patients across the United States.”

Saurini joins Dendreon with over 30 years of experience in quality assurance and regulatory affairs across pharmaceutical and medical device industries. She most recently served as Vice President of Quality at TissueTech, where she assured product, systems, and site compliance as the regulatory landscape of regenerative medicine evolved. Prior to her role at TissueTech, Saurini led Cryolife’s quality function at the corporate level to meet business needs across domestic and international sites.

“Sherry is a seasoned industry expert whose creative problem-solving capabilities, strong work ethic, and team-based approach make her the ideal fit for our business as Dendreon continues to grow,” said O’Neill. “Her leadership experience in full life cycle pharmaceuticals, biologics, and combination products will be essential to our business as we seek to advance the future of cell therapy.”

About Dendreon

Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells and has been prescribed to over 40,000 men with advanced prostate cancer in the U.S. since 2010. Dendreon is headquartered in Seal Beach, Calif. For more information, please visit www.dendreon.com.

Source

Recent Articles